ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR206/040/SRR20652440/SRR20652440.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR206/037/SRR20652437/SRR20652437.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR206/033/SRR20652433/SRR20652433.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR206/041/SRR20652441/SRR20652441.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR206/038/SRR20652438/SRR20652438.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR206/039/SRR20652439/SRR20652439.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR206/036/SRR20652436/SRR20652436.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR206/035/SRR20652435/SRR20652435.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR206/034/SRR20652434/SRR20652434.fastq.gzprimaryOK200GenomicsGuangdong Medical Universityhttps://www.ebi.ac.uk/ena/browser/view/PRJNA862390Homo sapiensxref:PubMed:37456058To explore the characteristics of senescent melanoma cells induced by vemurafenib or cisplatin, melanoma A375 cells were treated with vemurafenib and cisplatin, respectively. The senescent phenotypes were verified by β-gal staining, EdU assay, cell morphology and the senescence-related pathways. RNA-seq was performed to explore the differentially expressed genes in the senescent cells induced by vemurafenib or cisplatin. Overall design: Melanoma A375 cells were treated with vemurafenib (10 μM) for 3 days or with cisplatin (2 μM) for 1 day and then returned to normal culture conditions. At day 7 after the treatment, A375 cells were collected and used for RNA-seq and other detections. Normal cultured A375 cells were simultaneously collected and acted as negative control.ENAfalseVemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistanceVemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance2025-09-242023-07-08PRJNA862390GSE209769960637456058